Peculiarities of vascular remodeling in patients with chronic kidney disease stage 5D: prognostic role of the intima-media thickness


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. to assess the factors influence the intima-media thickness (IMT) in patients with ckd stage sd, as a key marker of vascular remodeling, reflecting the severity of endothelial dysfunction. material and methods. the study included 40 patients (22 men and 18 women) with chronic kidney disease receiving hemodialysis (HD) treatment. the average age of the patients was S8.9±13.i years. the mean duration of the disease leading to end-stage renal disease (ESRD) was 10.9±i.s years, the mean duration of renal replacement therapy (RRT) was S3.6±7.s months. In all patients, clinical and anamnestic data were assessed, laboratory studies, bioimpedansometry were performed, ultrasound examination of the carotid arteries was performed, and the imt was determined. statistical analysis was performed using statistica io.o software. results. it was found that with age in patients with ckd sd, the imt of the common carotid artery (CCA) increased (r=0.5S; p<0.05). the duration of renal dysfunction was associated with an increase in cca imt (r=0.19; p<0.0S). an increase in the cca imt was found in hypoalbuminemia, hyperglycemia, as well as an increase in the level of il-6. the survival rate of patients in the group 2 years after the start of follow-up was 80%. when assessing the cca imt, it was found that among the deceased, this indicator was significantly higher than in the group of survivors and amounted to 1.02±0.11 mm versus 0.8±0.4 mm, respectively (P<0.05). Conclusion. thus, an increase in il-6 levels, duration of ckd, electrolyte imbalance, hypoalbuminemia, hyperglycemia, and an increase in renal arterial vascular resistance were accompanied by an increase in the likelihood of an increase in cca imt. increased in cca imt has also been associated with a poor prognosis.

Full Text

Restricted Access

About the authors

Marina N. Kolomyitseva

Rostov State Medical University

Email: marina_matlaeva@mail.ru
post-graduate student of the Department of Internal Diseases #2

Mitkhat Z. Gasanov

Rostov State Medical University

Email: mitkhat@mail.ru
Cand.Sci. (Med.), Associate Professor of the Department of Internal Diseases #1

Mikhail M. Batyushin

Rostov State Medical University

Email: batjushin-m@rambler.ru
Dr. Sci. (Med.), Professor, Professor of the Department of Internal Diseases #2

Ogannes M. Manukyan

Rostov State Medical University

Email: hovo59@yandex.ru
Resident of the Department of Cardiology, Rheumatology and Functional Diagnostics

Liliya I. Rudenko

Regional Consultative and Diagnostic Center, advisory department, Rostov-on-Don

Email: rudenko.liliya@mail.ru
Cand.Sci. (Med.), nephrologist of the Regional Consultative and Diagnostic Center

References

  1. Vallianou N.G., Mitesh S., Gkogkou A., Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr. Cardiol. Rev. 2019;15(1):55-63. doi: 10.2174/1573403X14666180711124825
  2. Батюшин М.М. Хроническая болезнь почек: современное состояние проблемы. Рациональная фармакотерапия в кардиологии. 2020;16(6):938 47. doi: 10.20996/1819-6446-2020-11-06
  3. Крю Д., Белло А., Саади Г. Заболевания почек: бремя болезни и доступность медицинской помощи. Нефрология. 2019;23(2):9-17. doi: 10.24884/1561-6274-2019-23-2-9-17
  4. Котенко О.Н., Васина Н.В., Марченкова Л.В., Лысенко М.А. Состояние заместительной терапии хронической почечной недостаточности в Москве в 2015-2020 гг. Клиническая нефрология. 2021;1:13-19. Doi: https://dx.doi.org/10.18565/nephrology.2021.1.13-19
  5. Шилов Е.М., Котенко О.Н., Шилова М.М. и др. Нефрологическая служба Российской Федерации в 2019-2020 г.: отчет Президиума Профильной комиссии по нефрологии Экспертного Совета Минздрава России. Клиническая нефрология. 2020;4:5-35. Doi: https://dx.doi.org/10.18565/nephrology.2020.4.5-14
  6. Thompson S., James M., Wiebe N., et al. Cause of death in patients with reduced kidney function. J. Am. Soc. Nephrol. 2015;26:25042-511. doi: 10.1681/ASN.2014070714
  7. Tonelli M., Muntner P., Lloyd A. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet. (Lond. Engl.) 2012;380:807-14. Doi: 10.1016/ S0140-6736(12)60572-8
  8. Marx N., Noels H., Jankowski J., et al. Mechanisms of cardiovascular complications in chronic kidney disease: Research focus of the transregional research consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2018;107:1201-26. doi: 10.1007/s00392-018-1260-0
  9. Камышникова Л.А., Ефремова О.А., Пивовар Р.С. Особенности кардиоренальных взаимоотношений у больных с хронической болезнью почек. Современное состояние проблемы. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2017;5(254):13-21
  10. Noels H., Jankowski J. Editorial on the Special Issue “Comorbidities in Chronic Kidney Disease”. Toxins. (Basel). 2020;12(6):384. Doi: 10.3390/ toxins12060384.
  11. Major R.W., Cheng M.R.I., Grant R.A., et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. doi: 10.1371/journal.pone.0192895.
  12. Provenzano M., Coppolino G., Faga T., et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev. Cardiovasc. Med. 2019;20(4):209-20. doi: 10.31083/j.rcm.2019.04.548.
  13. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Провоспалительные цитокины у больных с хронической болезнью почек: в фокусе интерлейкин-6. Архивъ внутренней медицины. 2019;9(6):428-33. https://doi.org/10.20514/2226-6704-2019-9-6-428-433
  14. Roumeliotis S., Mallamaci F., Zoccali C. Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. J. Clin. Med. 2020;9(8):2359. doi: 10.3390/jcm9082359.
  15. Kumar K.S., Lakshmi A.Y., Srinivasa Rao P.V.L.N., Das G.C., Kumar V.S. Carotid intima-media thickness in patients with end-stage renal disease. Indian J. Nephrol. 2009;19(1):13-4. doi: 10.4103/0971-4065.50674.
  16. Muzasti R.A., Hariman H., Daulay E.R. Interleukin 6 concentration elevation as a risk of carotid intima-media thickness in chronic kidney disease patients with dialysis. Med. Glas. (Zenica). 2020;17(2):346-51. Doi: 10.17392/ 1172-20.
  17. Yamada S., Giachelli C.M. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. Bone. 2017;100:87-93. Doi: 10.1016/ j.bone.2016.11.012.
  18. Муркамилов И.Т. Взаимосвязь между концентрацией фактора роста фибробластов-23 и показателями центральной гемодинамики у больных с хронической болезнью почек. Клиническая нефрология. 2020;1:33-38. doi: 10.18565/nephroiogy.2020.1.33-38.
  19. Itkonen S.T., Karp H.J., Kemi V.E., et al. Associations among total and food additive phosphorus intake and carotid intima-media thickness a crosssectional study in a middle-aged population in Southern Finland. Nutr J. 2013;12:94. doi: 10.1186/1475-2891-12-94.
  20. Kuswardhani R.T., Wiradharma K.G., Kandarini Y. Factors associated with carotid intima-media thickness in patients on maintenance hemodialysis. Int. J. Gen. Med. 2018;12:1-6. doi: 10.2147/IJGM.S178276.
  21. Коломыйцева М.Н., Гасанов М.З., Батюшин М.М. Вклад системного воспаления в развитие сосудистого ремоделирования у пациентов с хронической болезнью почек и саркопенией. Терапия. 2021;5:39-46. Doi: https://dx.doi.org/10.18565/therapy.2021.5.39-46.
  22. Frati-Munari A.C. Medical significance of endothelial glycocalyx. Arch. Cardiol. Mex. 2013;83(4):303-12. doi: 10.1016/j.acmx.2013.04.015.
  23. Kubota K., Sakaguchi Y., Hamano T. et al. Prognostic value of hypochloremia versus hyponatremia among patients with chronic kidney disease-a retrospective cohort study. Nephrol Dial Transplant. 2020;35(6):987-994. Doi: 10.1093/ ndt/gfy299.
  24. Bulut A., Avci B. Carotid intima-media thickness values are significantly higher in patients with prediabetes compared to normal glucose metabolism. Medicine (Baltimore). 2019;98(44):e17805. doi: 10.1097/MD.0000000000017805.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies